357 related articles for article (PubMed ID: 33726710)
21. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
[TBL] [Abstract][Full Text] [Related]
22. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.
Gahramanov S; Varallyay C; Tyson RM; Lacy C; Fu R; Netto JP; Nasseri M; White T; Woltjer RL; Gultekin SH; Neuwelt EA
CNS Oncol; 2014 Nov; 3(6):389-400. PubMed ID: 25438810
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
25. A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma Multiforme.
Hao Y; Li X; Chen H; Huo H; Liu Z; Tian F; Chai E
World Neurosurg; 2019 Aug; 128():e427-e433. PubMed ID: 31042598
[TBL] [Abstract][Full Text] [Related]
26. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
27. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients.
Pouleau HB; Sadeghi N; Balériaux D; Mélot C; De Witte O; Lefranc F
Int J Oncol; 2012 Apr; 40(4):923-8. PubMed ID: 22086066
[TBL] [Abstract][Full Text] [Related]
28. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK
J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
[TBL] [Abstract][Full Text] [Related]
30. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
[TBL] [Abstract][Full Text] [Related]
31. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE
Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987
[TBL] [Abstract][Full Text] [Related]
32. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Ryu JY; Min KL; Chang MJ
PLoS One; 2019; 14(12):e0225599. PubMed ID: 31790459
[TBL] [Abstract][Full Text] [Related]
33. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
[TBL] [Abstract][Full Text] [Related]
35. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
36. Survival Analysis of Glioblastoma Multiforme.
Witthayanuwat S; Pesee M; Supaadirek C; Supakalin N; Thamronganantasakul K; Krusun S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2613-2617. PubMed ID: 30256068
[TBL] [Abstract][Full Text] [Related]
37. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
[TBL] [Abstract][Full Text] [Related]
39. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
40. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]